Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331115

Institution ID

3331115

Institution full name and acronym

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford

Institution countries

United Kingdom

Type of institution

Educational Institution
Hospital/Clinic/Other health care facility

Institution role

Researcher

Institution website

ENCePP partner

No
Institution description
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

An Assessment of a relationship between the exposure to COVID-19 vaccines and risk of thrombotic thrombocytopenia syndrome ATTEST study (Association of the risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 vaccines)
CharacTeristics of treAtment response to hIgh dose ICS/LABA vs. Medium or high dOse ICS/LABA + LAMA in patients with uncontRolled moderate to severe asthma on medium dose ICS/LABA - TAILOR study
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in patients with asthma or COPD
Excess risk and predictors of fracture/s following bariatric surgery for obese patients in the NHS: a real-world self-controlled case series and cohort study
Multinational Observational Database Study on Imminent Osteoporotic Fracture Risk: Stage 1 (IFRISK)
Quantitative bias analysis for outcome phenotype error correction in comparative effect estimation: an empirical evaluation and simulation study (QBA evaluation)
Risk-benefit and costs of unicompartmental (compared to total) knee replacement for patients with multiple co-morbidities: a non-randomised study, and different novel approaches to minimize confounding (UTMOST)
The comparative safety of first-line conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI)
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study